|
Peptides and Vaccines to inhibit Gonorrhoeae - (HJF 301-12)
Gonorrhoeae, a mucosal pathogen of the lower urogenital tract is remarkable in its capacity for antibiotic resistance. Its Multiple Transferable Resistance system (MTr) is known to enhance pathogen survival. Researchers at the Uniformed Services University (USU) and the Henry M. Jackson Foundation (HJF) have isolated the MtrE protein with possible application...
Published: 3/19/2026
|
Updated: 1/16/2026
|
Inventor(s): Ann Jerse, Amanda DeRocco
Keywords(s): Antibiotic Resistance, Antibodies, Antimicrobial, Inoculate, Neisseria gonorrhoeae, Peptide, Urogenital Tract, Vaccines
Category(s): Diagnostic, Therapeutic
|
|
Intranasal Insulin as a Treatment/Preventative Measure for Brain Injuries - (HJF 377-14)
Introduction
Researchers at the Uniformed Services University of the Health Sciences (USUHS) and HealthPartners Institute for Education and Research (HealthPartners) have discovered that intranasal delivery of insulin has the potential to treat and/or prevent injury to the brain. Beneficial outcomes were found in rats with moderate traumatic brain...
Published: 3/20/2026
|
Updated: 12/22/2025
|
Inventor(s): Kimberly Byrnes, Fiona Brabazon, William Frey II, Leah Bresin Hanson
Keywords(s): Insulin, Intranasal, Traumatic Brain Injury
Category(s): Therapeutic
|
|
Complex Natural Homogenates for Treating Allergies and Autoimmune Diseases (HJF 357-13)
Studies in humans and animals have demonstrated that infection with parasitic worms is protective against a range of chronic inflammatory diseases. These include inflammatory bowel disease, environmental allergies, asthma, and autoimmune diseases such as Type 1 diabetes, multiple sclerosis, and rheumatoid arthritis. Parasitic worm infections modulate...
Published: 3/19/2026
|
Updated: 11/7/2025
|
Inventor(s): Edward Mitre, Marina Torrero, Belinda Jackson
Keywords(s): Immune Balance, Natural Supplement, Nutraceutical Development, Safe Immune Modulation, Type 1 Diabetes Prevention, Worm Extract
Category(s): Therapeutic
|
|
Filarial Intestinal Antigens as Vaccine Candidates and Testing in Novel Animal Model of Filariasis - (HJF 378-14)
Introduction
Filariae are tissue-invasive parasitic nematodes that cause human diseases such as lymphatic filariasis, river blindness and African eyeworm; affecting over 200 million people worldwide. In addition to human disease, filarial parasites infect dogs and cats causing heartworm infections. Currently, no vaccine exists to prevent either human...
Published: 3/20/2026
|
Updated: 10/29/2025
|
Inventor(s): Edward Mitre, Christopher Morris, Sasisekhar Bennuru, Thomas Nutman
Keywords(s): B. malayi, Filarial Disease, Heartworm, Immunogen, Peptide, Vaccines
Category(s): Research Tool, Therapeutic
|
|
Molecular Predictors of Lung Adenocarcinoma Survival (HJF 602-21)
Research by Henry M. Jackson Foundation (HJF), Uniformed Services University (USU), and Defense Health Agency (DHA) scientists focused on identifying protein and RNA expression signatures that can differentiate between aggressive and metastasis-free lung adenocarcinoma (LUAD) tumors. These signatures were validated against National Cancer Institute’s...
Published: 3/20/2026
|
Updated: 5/30/2025
|
Inventor(s): Matthew Wilkerson, Robert Browning Jr, Craig Shriver
Keywords(s): LUAD Tumor, Lung Adenocarcinoma and Cancer, Metastasis-Free Survival, Protein
Category(s): Therapeutic
|
|
Isoflurane Administration as a Method for Neuroprotection in Organophosphate Poisoning (HJF 620-22 and HJF 441-16)
Organophosphate-based chemical agents (OPs), including nerve agents and certain neurotoxic pesticides such as paraoxon, are potent acetylcholinesterase inhibitors that cause severe convulsions and prolonged seizures, including progression to status epilepticus, potentially leading to irreversible central nervous system (CNS) damage if not treated promptly....
Published: 9/15/2025
|
Updated: 5/9/2025
|
Inventor(s): Aryan Namboodiri, John Moffett, Narayanan Vasudevan
Keywords(s): CNS, Neuroprotection, Organophosphate, Pesticide Poisoning, Seizure, Status Epilepticus
Category(s): Therapeutic, Medical Device
|
|
Small Molecule Therapeutics for Acute Myeloid Leukemia and Solid Tumors (HJF 490-17)
A technology related to novel methods of using small molecule compounds for treating myeloid neoplasms and solid tumor is available for licensing or collaboratively developing from HJF.
Applications and Advantages
Novel therapeutic targets for treating AML
Targeted therapy for cancer patients with overexpression or activating mutation of SETBP1
Innovation...
Published: 3/20/2026
|
Updated: 2/24/2025
|
Inventor(s): Yang (Dennis) Du, Nhu Nguyen
Keywords(s): Acute Myeloid Leukemia, AML, Cancer, Leukemia, Oncogene, SETBP1, Small Molecule, Therapeutics
Category(s): Therapeutic
|
|
Novel Vaccine Enhancers - (HJF 642-23)
Researchers at Henry M. Jackson Foundation (HJF), Uniformed Services University of the Health Sciences (USU), and Leidos Biomedical Research, Inc. (Leidos) have developed improvements to the effectiveness of mRNA vaccines. Such enhancements could reduce the number of doses needed for maximal protection, enhance vaccine durability, and reduce associated...
Published: 3/19/2026
|
Updated: 2/19/2025
|
Inventor(s): Edward Mitre, Elizabeth Graydon, Stephen Anderson
Keywords(s): mRNA, Therapeutics, Vaccines
Category(s): Therapeutic
|
|
Diagnostic Tool for High-grade Serous Ovarian Cancer - (HJF 616-21)
Researchers at HJF, Inova Fairfax Hospital (IFH), and the Peter MacCallum Cancer Centre (PMCC) have identified orthogonal protein and transcript-based biomarkers correlating with Homologous Recombination Deficiency (HRD). This may lead to a companion clinical diagnostic assay to prioritize High-Grade Serous Ovarian Cancer (HGSOC) patients for targeted...
Published: 8/22/2025
|
Updated: 12/12/2024
|
Inventor(s): Nicholas Bateman, Tamara Abulez, Thomas Conrads, George Larry Maxwell, Dale Garsed, David Bowtell, Ahwan Pandey
Keywords(s): Assay, Biomarker Assay, Companion Diagnostic, DDR, DNA Damage Repair, HGSOC, High-Grade Serous Ovarian Carcinoma, Ovarian Cancer, PARP Inhibitors
Category(s): Therapeutic, Diagnostic
|
|
Lymphocyte Antigen 6 (Ly6) Targeted Cancer Immunotherapy - (HJF 649-23)
A technology related to using antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) transduced immune cells that selectively targets Ly6 family of proteins overexpressed in cancer cells and has the potential to be effective in treating ovarian, colorectal, gastric, breast, and lung cancer without off-target effects. This HJF technology...
Published: 3/19/2026
|
Updated: 5/6/2024
|
Inventor(s): Geeta Upadhyay
Keywords(s): Antibodies, Antibody Conjugates, Antibody Drug Conjugate, Cancer, CAR, Ly6, Lymphocite Antigen 6
Category(s): Therapeutic
|
